#BEGIN_DRUGCARD DB08819

# AHFS_Codes:
52:40.28

# ATC_Codes:
S01EE05

# Absorption:
Following instillation, tafluprost is absorbed through the cornea and is hydrolyzed to the biologically active acid metabolite, tafluprost acid. Tafluprost is an ester which makes the drug lipophillic enough to be quickly absorbed through. When administered to the eye, the peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax) of tafluprost acid in healthy subjects was 26 pg/mL and 10 minutes respectively. a
AUC, tafluprost acid = 394 pg*min/mL - 432 pg*min/mL.

# Biotransformation:
Tafluprost is an ester prodrug which is rapidly hydrolyzed by corneal esterases to form its biologically active acid metabolite. Tafluprost acid is further metabolized via fatty acid β-oxidation and phase II conjugation into 1,2,3,4-tetranor acid.

# Brand_Mixtures:
Not Available

# Brand_Names:
Saflutan
Taflotan
Zioptan

# CAS_Registry_Number:
209860-87-7

# ChEBI_ID:
66899

# Chemical_Formula:
C25H34F2O5

# Chemical_IUPAC_Name:
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl]hept-5-enoate

# Chemical_Structure:
Not Available

# Creation_Date:
2012-02-24 10:29:58 -0700

# DPD_Drug_ID_Number:
2240434

# Description:
A prostaglandin analogue ester prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. Chemically, tafluprost is a fluorinated analog of prostaglandin F2-alpha. Tafluprost was approved for use in the U.S. on February 10, 2012.

# Dosage_Forms:
Solution	Ophthalmic

# Drug_Category:
Ophthalmics
Prostaglandin analogues

# Drug_Interactions:
Not Available

# Drug_Reference:
15037111	Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, Gabelt BT, Kaufman PL, Hara H: Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004 Apr;78(4):767-76.
19477946	Fukano Y, Kawazu K: Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats. Drug Metab Dispos. 2009 Aug;37(8):1622-34. doi: 10.1124/dmd.108.024885. Epub 2009 May 28.
21858491	Pantcheva MB, Seibold LK, Awadallah NS, Kahook MY: Tafluprost: a novel prostaglandin analog for treatment of glaucoma. Adv Ther. 2011 Sep;28(9):707-15. Epub 2011 Aug 18.
21916788	Papadia M, Bagnis A, Scotto R, Traverso CE: Tafluprost for glaucoma. Expert Opin Pharmacother. 2011 Oct;12(15):2393-401.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
4.05

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Insoluble

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Tafluprost

# HET_ID:
TFO

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C25H34F2O5/c1-18(2)32-24(30)13-9-4-3-8-12-20-21(23(29)16-22(20)28)14-15-25(26,27)17-31-19-10-6-5-7-11-19/h3,5-8,10-11,14-15,18,20-23,28-29H,4,9,12-13,16-17H2,1-2H3/b8-3-,15-14+/t20-,21-,22+,23-/m1/s1

# InChI_Key:
InChIKey=WSNODXPBBALQOF-VEJSHDCNSA-N

# Indication:
Tafluprost is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

# KEGG_Compound_ID:
C12599

# KEGG_Drug_ID:
D06274

# LIMS_Drug_ID:
8827

# Mechanism_Of_Action:
Tafluprost acid is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and humans suggest that the main mechanism of action is increased uveoscleral outflow.

# Melting_Point:
87.5 °C

# Molecular_Weight_Avg:
452.5313

# Molecular_Weight_Mono:
452.237430608

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/vir1605.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA165958432

# Pharmacology:
Tafluprost is a novel prostaglandin analog with a high affinity for the fluoroprostaglandin (FP) receptor PGF2α. Tafluprost has an affinity for the FP receptor that is approximately 12 times higher than that of the carboxylic acid of latanoprost, but with almost no potential to bind to other receptors.

# Predicted_LogP_Hydrophobicity:
4.46

# Predicted_LogS:
-4.9

# Predicted_Water_Solubility:
5.28e-03 g/l

# Primary_Accession_No:
DB08819

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/zioptan-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1

# State:
liquid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
AFP-168

# Synthesis_Reference:
Not Available

# Toxicity:
Most common ocular adverse reaction is conjunctival hyperemia (range 4% – 20%).

# Update_Date:
2013-06-05 17:11:55 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Tafluprost

# pKa_Isoelectric_Point:
5.5-6.7

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
PTGS2

# Phase_1_Metabolizing_Enzyme_1_ID:
290

# Phase_1_Metabolizing_Enzyme_1_Name:
Prostaglandin G/H synthase 2

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Prostaglandin G/H synthase 2 precursor
MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
STEL

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P35354

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
21858491	Pantcheva MB, Seibold LK, Awadallah NS, Kahook MY: Tafluprost: a novel prostaglandin analog for treatment of glaucoma. Adv Ther. 2011 Sep;28(9):707-15. Epub 2011 Aug 18.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PTGFR

# Drug_Target_1_GenBank_ID_Gene:
L24470

# Drug_Target_1_GenBank_ID_Protein:
456564

# Drug_Target_1_GeneCard_ID:
PTGFR

# Drug_Target_1_Gene_Name:
PTGFR

# Drug_Target_1_Gene_Sequence:
>1080 bp
ATGTCCATGAACAATTCCAAACAGCTAGTGTCTCCTGCAGCTGCGCTTCTTTCAAACACA
ACCTGCCAGACGGAAAACCGGCTTTCCGTATTTTTTTCAGTAATCTTCATGACAGTGGGA
ATCTTGTCAAACAGCCTTGCCATCGCCATTCTCATGAAGGCATATCAGAGATTTAGACAG
AAGTCCAAGGCATCGTTTCTGCTTTTGGCCAGCGGCCTGGTAATCACTGATTTCTTTGGC
CATCTCATCAATGGAGCCATAGCAGTATTTGTATATGCTTCTGATAAAGAATGGATCCGC
TTTGACCAATCAAATGTCCTTTGCAGTATTTTTGGTATCTGCATGGTGTTTTCTGGTCTG
TGCCCACTTCTTCTAGGCAGTGTGATGGCCATTGAGCGGTGTATTGGAGTCACAAAACCA
ATATTTCATTCTACGAAAATTACATCCAAACATGTGAAAATGATGTTAAGTGGTGTGTGC
TTGTTTGCTGTTTTCATAGCTTTGCTGCCCATCCTTGGACATCGAGACTATAAAATTCAG
GCGTCGAGGACCTGGTGTTTCTACAACACAGAAGACATCAAAGACTGGGAAGATAGATTT
TATCTTCTACTTTTTTCTTTTCTGGGGCTCTTAGCCCTTGGTGTTTCATTGTTGTGCAAT
GCAATCACAGGAATTACACTTTTAAGAGTTAAATTTAAAAGTCAGCAGCACAGACAAGGC
AGATCTCATCATTTGGAAATGGTAATCCAGCTCCTGGCGATAATGTGTGTCTCCTGTATT
TGTTGGAGCCCATTTCTGGTTACAATGGCCAACATTGGAATAAATGGAAATCATTCTCTG
GAAACCTGTGAAACAACACTTTTTGCTCTCCGAATGGCAACATGGAATCAAATCTTAGAT
CCTTGGGTATATATTCTTCTACGAAAGGCTGTCCTTAAGAATCTCTATAAGCTTGCCAGT
CAATGCTGTGGAGTGCATGTCATCAGCTTACATATTTGGGAGCTTAGTTCCATTAAAAAT
TCCTTAAAGGTTGCTGCTATTTCTGAGTCACCAGTTGCAGAGAAATCAGCAAGCACCTAG

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
8300593	Abramovitz M, Boie Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slipetz DM, Grygorczyk R: Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem. 1994 Jan 28;269(4):2632-6.

# Drug_Target_1_HGNC_ID:
HGNC:9600

# Drug_Target_1_HPRD_ID:
08988

# Drug_Target_1_ID:
672

# Drug_Target_1_Locus:
1p31.1

# Drug_Target_1_Molecular_Weight:
40055

# Drug_Target_1_Name:
Prostaglandin F2-alpha receptor

# Drug_Target_1_Number_of_Residues:
359

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Prostaglandin F2-alpha receptor
MSMNNSKQLVSPAAALLSNTTCQTENRLSVFFSVIFMTVGILSNSLAIAILMKAYQRFRQ
KSKASFLLLASGLVITDFFGHLINGAIAVFVYASDKEWIRFDQSNVLCSIFGICMVFSGL
CPLLLGSVMAIERCIGVTKPIFHSTKITSKHVKMMLSGVCLFAVFIALLPILGHRDYKIQ
ASRTWCFYNTEDIKDWEDRFYLLLFSFLGLLALGVSLLCNAITGITLLRVKFKSQQHRQG
RSHHLEMVIQLLAIMCVSCICWSPFLVTMANIGINGNHSLETCETTLFALRMATWNQILD
PWVYILLRKAVLKNLYKLASQCCGVHVISLHIWELSSIKNSLKVAAISESPVAEKSAST

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum

# Drug_Target_1_SwissProt_ID:
P43088

# Drug_Target_1_SwissProt_Name:
PF2R_HUMAN

# Drug_Target_1_Synonyms:
PGF receptor
PGF2 alpha receptor
Prostanoid FP receptor

# Drug_Target_1_Theoretical_pI:
9.11

# Drug_Target_1_Transmembrane_Regions:
32-54
70-90
110-131
153-175
199-224
251-267
286-307

#END_DRUGCARD DB08819
